News Lila Sciences' $235m first round, and other biofinancings Recent biotech financings include big rounds for Lila Sciences, Odyssey, and Ollin, with ARTHEx, Dualitas, and YolTech also in on the action.
News After a long biotech IPO lull, LB Pharma chances its arm After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.
News Treeline's $200m Series A extension, and other biofinancings Recent biotech financings include a $200m round for Treeline, with Enveda, Wugen, CHARM Therapeutics, and MRM Health also in on the action.
Market Access Biotech ≠ tech: Why venture capital needs a new playbook for... Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1
News Strand raises $153m for RNA meds, and other bio financings Recent financings in biotech include a $153m Series B for programmable mRNA developer Strand, plus rounds for Artbio, Minghui, and Chai Discovery.
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.